

2019 Future of Visceral Pain R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/2B2258F6613EN.html>

Date: February 2019

Pages: 85

Price: US\$ 2,199.00 (Single User License)

ID: 2B2258F6613EN

Abstracts

The global demand for Visceral Pain treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Visceral Pain pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Visceral Pain pipeline companies from advancing their products into Phase 3 or Phase 4.

Visceral Pain Report Description-

The 2019 pipeline study on Visceral Pain pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Visceral Pain pipeline compounds.

The Visceral Pain pipeline guide presents information on all active drugs currently being developed for Visceral Pain. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Visceral Pain pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Visceral Pain drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Visceral Pain product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Visceral Pain pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Visceral Pain pipeline report includes-

An overview of Visceral Pain disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Visceral Pain pipeline

Company wise list of Visceral Pain pipeline

Mechanism of Action wise Visceral Pain pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Visceral Pain pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Visceral Pain pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Visceral Pain pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL VISCERAL PAIN PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Visceral Pain Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
 - 3.2.1 Pre-clinical
 - 3.2.2 Discovery
 - 3.2.3 Phase
 - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
 - 3.3.1 Phase
 - 3.3.2 Pre-registration
- 3.4 Companies involved in Visceral Pain pipeline, H1- 2019
- 3.5 Mechanism of Action wise Visceral Pain Pipeline Candidates

4 ADDEX THERAPEUTICS LTD VISCERAL PAIN PIPELINE DETAILS

- 4.1 Addex Therapeutics Ltd Business Profile
- 4.2 Addex Therapeutics Ltd Visceral Pain Drug Details
- 4.3 Drug Snapshot
 - 4.3.1 Originator
 - 4.3.2 Collaborator/Co-Developer
 - 4.3.3 Route of Administration
 - 4.3.4 Orphan Drug/Fast Track/Special Designation
 - 4.3.5 Geography
 - 4.3.6 Type of Molecular Entity
 - 4.3.7 Current Status

- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5 ALGOMEDIX INC VISCERAL PAIN PIPELINE DETAILS

- 5.1 Algomedix Inc Business Profile
- 5.2 Algomedix Inc Visceral Pain Drug Details
- 5.3 Drug Snapshot
 - 5.3.1 Originator
 - 5.3.2 Collaborator/Co-Developer
 - 5.3.3 Route of Administration
 - 5.3.4 Orphan Drug/Fast Track/Special Designation
 - 5.3.5 Geography
 - 5.3.6 Type of Molecular Entity
 - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6 ANAVEX LIFE SCIENCES CORP VISCERAL PAIN PIPELINE DETAILS

- 6.1 Anavex Life Sciences Corp Business Profile
- 6.2 Anavex Life Sciences Corp Visceral Pain Drug Details
- 6.3 Drug Snapshot
 - 6.3.1 Originator
 - 6.3.2 Collaborator/Co-Developer
 - 6.3.3 Route of Administration
 - 6.3.4 Orphan Drug/Fast Track/Special Designation
 - 6.3.5 Geography
 - 6.3.6 Type of Molecular Entity
 - 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7 ARENA PHARMACEUTICALS INC VISCERAL PAIN PIPELINE DETAILS

- 7.1 Arena Pharmaceuticals Inc Business Profile
- 7.2 Arena Pharmaceuticals Inc Visceral Pain Drug Details
- 7.3 Drug Snapshot
 - 7.3.1 Originator
 - 7.3.2 Collaborator/Co-Developer
 - 7.3.3 Route of Administration
 - 7.3.4 Orphan Drug/Fast Track/Special Designation
 - 7.3.5 Geography
 - 7.3.6 Type of Molecular Entity
 - 7.3.7 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8 ASTELLAS PHARMA INC VISCERAL PAIN PIPELINE DETAILS

- 8.1 Astellas Pharma Inc Business Profile
- 8.2 Astellas Pharma Inc Visceral Pain Drug Details
- 8.3 Drug Snapshot
 - 8.3.1 Originator
 - 8.3.2 Collaborator/Co-Developer
 - 8.3.3 Route of Administration
 - 8.3.4 Orphan Drug/Fast Track/Special Designation
 - 8.3.5 Geography
 - 8.3.6 Type of Molecular Entity
 - 8.3.7 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9 ASTRAZENECA VISCERAL PAIN PIPELINE DETAILS

- 9.1 AstraZeneca Business Profile
- 9.2 AstraZeneca Visceral Pain Drug Details
- 9.3 Drug Snapshot

- 9.3.1 Originator
- 9.3.2 Collaborator/Co-Developer
- 9.3.3 Route of Administration
- 9.3.4 Orphan Drug/Fast Track/Special Designation
- 9.3.5 Geography
- 9.3.6 Type of Molecular Entity
- 9.3.7 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10 CADILA HEALTHCARE LTD VISCERAL PAIN PIPELINE DETAILS

- 10.1 Cadila Healthcare Ltd Business Profile
- 10.2 Cadila Healthcare Ltd Visceral Pain Drug Details
- 10.3 Drug Snapshot
 - 10.3.1 Originator
 - 10.3.2 Collaborator/Co-Developer
 - 10.3.3 Route of Administration
 - 10.3.4 Orphan Drug/Fast Track/Special Designation
 - 10.3.5 Geography
 - 10.3.6 Type of Molecular Entity
 - 10.3.7 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11 CHROMOCELL CORP VISCERAL PAIN PIPELINE DETAILS

- 11.1 Chromocell Corp Business Profile
- 11.2 Chromocell Corp Visceral Pain Drug Details
- 11.3 Drug Snapshot
 - 11.3.1 Originator
 - 11.3.2 Collaborator/Co-Developer
 - 11.3.3 Route of Administration
 - 11.3.4 Orphan Drug/Fast Track/Special Designation
 - 11.3.5 Geography

- 11.3.6 Type of Molecular Entity
- 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12 EISAI CO LTD VISCERAL PAIN PIPELINE DETAILS

- 12.1 Eisai Co Ltd Business Profile
- 12.2 Eisai Co Ltd Visceral Pain Drug Details
- 12.3 Drug Snapshot
 - 12.3.1 Originator
 - 12.3.2 Collaborator/Co-Developer
 - 12.3.3 Route of Administration
 - 12.3.4 Orphan Drug/Fast Track/Special Designation
 - 12.3.5 Geography
 - 12.3.6 Type of Molecular Entity
 - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13 ELI LILLY AND CO VISCERAL PAIN PIPELINE DETAILS

- 13.1 Eli Lilly and Co Business Profile
- 13.2 Eli Lilly and Co Visceral Pain Drug Details
- 13.3 Drug Snapshot
 - 13.3.1 Originator
 - 13.3.2 Collaborator/Co-Developer
 - 13.3.3 Route of Administration
 - 13.3.4 Orphan Drug/Fast Track/Special Designation
 - 13.3.5 Geography
 - 13.3.6 Type of Molecular Entity
 - 13.3.7 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details

13.7 Latest Drug Developments

14 GRUNENTHAL GMBH VISCERAL PAIN PIPELINE DETAILS

- 14.1 Grunenthal GmbH Business Profile
- 14.2 Grunenthal GmbH Visceral Pain Drug Details
- 14.3 Drug Snapshot
 - 14.3.1 Originator
 - 14.3.2 Collaborator/Co-Developer
 - 14.3.3 Route of Administration
 - 14.3.4 Orphan Drug/Fast Track/Special Designation
 - 14.3.5 Geography
 - 14.3.6 Type of Molecular Entity
 - 14.3.7 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

15 IRONWOOD PHARMACEUTICALS INC VISCERAL PAIN PIPELINE DETAILS

- 15.1 Ironwood Pharmaceuticals Inc Business Profile
- 15.2 Ironwood Pharmaceuticals Inc Visceral Pain Drug Details
- 15.3 Drug Snapshot
 - 15.3.1 Originator
 - 15.3.2 Collaborator/Co-Developer
 - 15.3.3 Route of Administration
 - 15.3.4 Orphan Drug/Fast Track/Special Designation
 - 15.3.5 Geography
 - 15.3.6 Type of Molecular Entity
 - 15.3.7 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action
- 15.6 Clinical/Pre-clinical Trial Details
- 15.7 Latest Drug Developments

16 KANGEN PHARMACEUTICALS CO LTD VISCERAL PAIN PIPELINE DETAILS

- 16.1 Kangen Pharmaceuticals Co Ltd Business Profile

16.2 Kangen Pharmaceuticals Co Ltd Visceral Pain Drug Details

16.3 Drug Snapshot

16.3.1 Originator

16.3.2 Collaborator/Co-Developer

16.3.3 Route of Administration

16.3.4 Orphan Drug/Fast Track/Special Designation

16.3.5 Geography

16.3.6 Type of Molecular Entity

16.3.7 Current Status

16.4 Drug Overview

16.5 Drug Mechanism of Action

16.6 Clinical/Pre-clinical Trial Details

16.7 Latest Drug Developments

17 KYORIN PHARMACEUTICAL CO LTD VISCERAL PAIN PIPELINE DETAILS

17.1 Kyorin Pharmaceutical Co Ltd Business Profile

17.2 Kyorin Pharmaceutical Co Ltd Visceral Pain Drug Details

17.3 Drug Snapshot

17.3.1 Originator

17.3.2 Collaborator/Co-Developer

17.3.3 Route of Administration

17.3.4 Orphan Drug/Fast Track/Special Designation

17.3.5 Geography

17.3.6 Type of Molecular Entity

17.3.7 Current Status

17.4 Drug Overview

17.5 Drug Mechanism of Action

17.6 Clinical/Pre-clinical Trial Details

17.7 Latest Drug Developments

18 LIPELLA PHARMACEUTICALS INC VISCERAL PAIN PIPELINE DETAILS

18.1 Lipella Pharmaceuticals Inc Business Profile

18.2 Lipella Pharmaceuticals Inc Visceral Pain Drug Details

18.3 Drug Snapshot

18.3.1 Originator

18.3.2 Collaborator/Co-Developer

18.3.3 Route of Administration

- 18.3.4 Orphan Drug/Fast Track/Special Designation
- 18.3.5 Geography
- 18.3.6 Type of Molecular Entity
- 18.3.7 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

19 NEURAXON PHARMA INC VISCERAL PAIN PIPELINE DETAILS

- 19.1 NeurAxon Pharma Inc Business Profile
- 19.2 NeurAxon Pharma Inc Visceral Pain Drug Details
- 19.3 Drug Snapshot
 - 19.3.1 Originator
 - 19.3.2 Collaborator/Co-Developer
 - 19.3.3 Route of Administration
 - 19.3.4 Orphan Drug/Fast Track/Special Designation
 - 19.3.5 Geography
 - 19.3.6 Type of Molecular Entity
 - 19.3.7 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

20 PFIZER INC VISCERAL PAIN PIPELINE DETAILS

- 20.1 Pfizer Inc Business Profile
- 20.2 Pfizer Inc Visceral Pain Drug Details
- 20.3 Drug Snapshot
 - 20.3.1 Originator
 - 20.3.2 Collaborator/Co-Developer
 - 20.3.3 Route of Administration
 - 20.3.4 Orphan Drug/Fast Track/Special Designation
 - 20.3.5 Geography
 - 20.3.6 Type of Molecular Entity
 - 20.3.7 Current Status
- 20.4 Drug Overview

- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

21 PIERRE FABRE PHARMACEUTICALS INC VISCERAL PAIN PIPELINE DETAILS

- 21.1 Pierre Fabre Pharmaceuticals Inc Business Profile
- 21.2 Pierre Fabre Pharmaceuticals Inc Visceral Pain Drug Details
- 21.3 Drug Snapshot
 - 21.3.1 Originator
 - 21.3.2 Collaborator/Co-Developer
 - 21.3.3 Route of Administration
 - 21.3.4 Orphan Drug/Fast Track/Special Designation
 - 21.3.5 Geography
 - 21.3.6 Type of Molecular Entity
 - 21.3.7 Current Status
- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details
- 21.7 Latest Drug Developments

22 UCB SA VISCERAL PAIN PIPELINE DETAILS

- 22.1 UCB SA Business Profile
- 22.2 UCB SA Visceral Pain Drug Details
- 22.3 Drug Snapshot
 - 22.3.1 Originator
 - 22.3.2 Collaborator/Co-Developer
 - 22.3.3 Route of Administration
 - 22.3.4 Orphan Drug/Fast Track/Special Designation
 - 22.3.5 Geography
 - 22.3.6 Type of Molecular Entity
 - 22.3.7 Current Status
- 22.4 Drug Overview
- 22.5 Drug Mechanism of Action
- 22.6 Clinical/Pre-clinical Trial Details
- 22.7 Latest Drug Developments

23 URIGEN PHARMACEUTICALS INC VISCERAL PAIN PIPELINE DETAILS

- 23.1 Urigen Pharmaceuticals Inc Business Profile
- 23.2 Urigen Pharmaceuticals Inc Visceral Pain Drug Details
- 23.3 Drug Snapshot
 - 23.3.1 Originator
 - 23.3.2 Collaborator/Co-Developer
 - 23.3.3 Route of Administration
 - 23.3.4 Orphan Drug/Fast Track/Special Designation
 - 23.3.5 Geography
 - 23.3.6 Type of Molecular Entity
 - 23.3.7 Current Status
- 23.4 Drug Overview
- 23.5 Drug Mechanism of Action
- 23.6 Clinical/Pre-clinical Trial Details
- 23.7 Latest Drug Developments

24 XIGEN SA VISCERAL PAIN PIPELINE DETAILS

- 24.1 Xigen SA Business Profile
- 24.2 Xigen SA Visceral Pain Drug Details
- 24.3 Drug Snapshot
 - 24.3.1 Originator
 - 24.3.2 Collaborator/Co-Developer
 - 24.3.3 Route of Administration
 - 24.3.4 Orphan Drug/Fast Track/Special Designation
 - 24.3.5 Geography
 - 24.3.6 Type of Molecular Entity
 - 24.3.7 Current Status
- 24.4 Drug Overview
- 24.5 Drug Mechanism of Action
- 24.6 Clinical/Pre-clinical Trial Details
- 24.7 Latest Drug Developments

25. LATEST VISCERAL PAIN DRUG PIPELINE DEVELOPMENTS, 2019

26. APPENDIX

- 26.1 About Us
- 26.2 Sources and Methodology

26.3 Contact Information

I would like to order

Product name: 2019 Future of Visceral Pain R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2B2258F6613EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2B2258F6613EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

